Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis
Frontiers in Cardiovascular Medicine · 20.05.2026 · 13
DOI: 10.3389/fcvm.2026.1834712 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 20.05.2026. Verfasst von Simon Wölbert und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Augsburg, Germany. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bioresorbable scaffolds aim to mitigate long-term complications of drug-eluting stents (DES). The bioresorbable magnesium scaffold Magmaris is an alternative, but its role in acute coronary syndrome (ACS) remains insufficiently studied. Therefore, we aimed to evaluate safety and efficacy of Magmaris in ACS and compare outcomes with DES.
Methods
We systematically searched PubMed, Embase and Cochrane Central Register of Controlled Trials for randomized and observational studies reporting outcomes of Magmaris in ACS. Primary outcome was target-lesion failure (TLF) defined as composite of cardiac death (CD), target-vessel myocardial infarction (TV-MI) and target-lesion revascularization (TLR) at one year. Secondary outcomes included scaffold/stent thrombosis (ST) and procedural success. Single-arm pooled event rates and pairwise comparisons were estimated using generalized linear mixed-effects models (GLMM).
Results
We included four studies ( n = 622 patients; 322 Magmaris, 300 DES) for pairwise analysis. At one year, no statistically significant difference in TLF was observed between Magmaris and DES (7.5% vs. 5.3%, OR 1.53, 95% CI 0.79–2.97; p = 0.21; I 2 = 54.7%), although confidence intervals were wide. TLR was significantly higher with Magmaris (6.8% vs. 3.0%, OR 2.63, 95% CI 1.17–5.90; p = 0.019; I 2 = 10.7%), while TV-MI, CD and ST did not differ significantly between groups. Twelve studies ( n = 1,391 patients) contributed single-arm analyses showing pooled 1-year incidence of TLF 4.97%, TLR 4.16% and ST 0.83%. Procedural success was 98.49% (95% CI 97.21–99.18; I 2 = 35.4%).
Conclusion
In ACS, Magmaris was associated with low observed ST rates, nevertheless, comparative safety and efficacy vs. DES remain uncertain due to limited and heterogeneous evidence. Higher TLR rates with Magmaris suggest that further technical improvements in next-generation magnesium scaffolds are needed before this strategy can be considered a robust alternative in ACS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Augsburg, Germany.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center IRCCS and Humanitas University, Rozzano, Milano, Italy.
- Cardiovascular Center Oberallgaeu-Kempten, Kempten, Germany.
Zitieren
APA
Wölbert, S., Escrihuela-Branz, P. F. F., Kühne, S. G., Patrignani, A., Chiarito, M., Torzewski, J., Raake, P. W. J., & Bongiovanni, D. (2026). Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1834712
Vancouver
Wölbert S, Escrihuela-Branz PFF, Kühne SG, Patrignani A, Chiarito M, Torzewski J, et al. Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1834712
BibTeX
@article{Wlbert2026,
author = {Wölbert, Simon and Escrihuela-Branz, Pablo F F and Kühne, Stephanie Gladys and Patrignani, Andrea and Chiarito, Mauro and Torzewski, Jan and Raake, Philip W J and Bongiovanni, Dario},
title = {Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1834712}
}
EUVIMED